Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancerTakaaki Fujimura(Unknown), Shigeki Yoshiura(Chugai Pharma (United States))npj Precision OncologyNovember 17, 202410.1038/s41698-024-00757-wCited by 7SaveCiteExport RISWatch citationsRelated PapersCombined blockade of <scp>GPX4</scp> and activated <scp>EGFR</scp>/<scp>HER3</scp> bypass pathways inhibits the development of <scp>ALK</scp>‐inhibitor‐induced tolerant persister cells in <scp><i>ALK</i></scp>‐fusion‐positive lung cancer|Molecular Oncology|2024|7Targeting ErbB and tankyrase1/2 prevent the emergence of drug tolerant persister cells in ALK fusion positive lung cancer|Research Square|2023|0